Huawei already tells you that you might be at risk of high blood sugar. Now the company says it has spent four years building something that could actually test for it.
The comment came from He Gang, CEO of Huawei's Consumer Business Group, during a recruitment event at Peking University. He said Huawei plans to release a blood sugar testing device, and that the technology behind it took four years to reach a point the company considered acceptable and ready for industrialisation.
That is a meaningful change in wording. Huawei has spent years describing blood sugar work as research. This is the first time the head of the consumer business has talked about shipping something.
What Huawei Actually Said, and What It Didn't
He Gang stopped at the headline. There is no product image, no name, no price, no launch window, and no explanation of how the sensing works.
We also don't know whether it's worn on the wrist, whether it's a wearable at all, or whether it measures continuously or on demand.
On a health announcement, that is most of the story missing.
Why the Obvious Reading Is Non-Invasive
There are two established ways to measure blood glucose today. Finger-prick meters, which need a drop of blood, and continuous glucose monitors, which use a filament under the skin.
Neither is pleasant, and both already exist in mature form. Spending four years of research to produce another version of either would be strange, which is why the natural read here is non-invasive sensing through the skin.
Huawei hasn't said that. It's an inference from the fact that the interesting version of this product is the one that doesn't need a needle.
If Huawei does end up claiming it measures glucose without drawing blood, regulatory clearance becomes the entire story. Every company that has chased this has run into the same wall: getting a number that holds up in a clinical setting, on a wrist, with all the movement and sweat and temperature swings that come with it.
Huawei Has Form for Strange Health Hardware
The reason to take this more seriously than a random executive aside is the Watch D3.
Huawei's blood pressure watch puts a tiny inflatable airbag inside the strap and takes genuine oscillometric readings, the same method a cuff at your doctor's office uses. Almost every other smartwatch that claims blood pressure tracking estimates it from pulse wave analysis instead, which is convenient and considerably vaguer.
That tells you Huawei is willing to build genuinely odd hardware in service of a health metric nobody else is doing properly. A blood sugar sensor that looks nothing like a normal watch would be entirely in character.
Risk Is Not Measurement
This distinction matters, because Huawei already ships something that sounds like the answer.
Several Huawei watches, including the recently launched Watch GT 7 series in compatible markets, assess your risk of elevated blood sugar. That's pattern analysis over your existing sensor data. It produces a warning, not a reading, and it does not give you a glucose value.
Risk assessment and measurement are different products, different claims, and very different regulatory paths. The Watch GT 7 does the first. He Gang is describing the second. Google draws the same distinction between an insulin resistance trend and an actual glucose reading.
There was also an earlier hint. A report in September 2025 claimed Huawei was developing an advanced blood sugar monitoring wearable for 2026, but it came from a Weibo tipster rather than Huawei, and there was very little behind it at the time. A statement from the head of the consumer business is a different class of evidence, even with everything it leaves out.
Bottom Line
Huawei has a genuine track record on hard health sensing, and the Watch D3 proves it will build unusual hardware to get there. A blood sugar measurement device, if that's what this is, would be the most ambitious version of that strategy yet.
But "ready for industrialisation" is a long way from a product on a shelf. Huawei hasn't given a date, a form factor, or a method, and the four-year timeline ends at a decision to move forward rather than a finished device. If this is non-invasive glucose measurement, the regulatory filing will be the real announcement.
Worth watching. Not yet worth planning around.
Sources: He Gang's remarks at a Peking University recruitment event, reported September 26, 2026 by IT Home, ifeng tech, Sina Weibo news and 17173, including the four-year research timeline and the industrialisation wording; Huawei's own product documentation for the Watch GT 7 series high blood sugar risk assessment feature, covering compatible markets and the fact that it assesses risk rather than measuring a glucose value; Huawei's Watch D3 launch material and specifications covering the oscillometric blood pressure system and its inflatable strap airbag; and the September 2025 Weibo tipster claim about a Huawei blood sugar monitoring wearable for 2026.
